Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
62 GBX | +6.90% | +8.77% | -26.19% |
Apr. 17 | AIM WINNERS & LOSERS: Inspecs confident but Scirocco eyes AIM exit | AN |
Apr. 17 | Inspecs hails "encouraging" recent trading after tepid start to 2024 | AN |
Summary
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.42 for the 2024 fiscal year.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-26.19% | 79.11M | C- | ||
+11.23% | 98.38B | B | ||
+9.93% | 39.34B | B | ||
-4.20% | 18.02B | B- | ||
-16.61% | 2.33B | D+ | ||
-10.04% | 1.51B | C+ | ||
+26.36% | 1.21B | - | ||
-34.97% | 755M | - | ||
-36.42% | 744M | B- | ||
-8.48% | 665M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SPEC Stock
- Ratings INSPECS Group plc